Artemis Medicare Services Limited (NSE:ARTEMISMED) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a good week for Artemis Medicare Services Limited (NSE:ARTEMISMED) shareholders, because the company has just released its latest quarterly results, and the shares gained 3.2% to ₹312. Artemis Medicare Services reported in line with analyst predictions, delivering revenues of ₹2.9b and statutory earnings per share of ₹6.56, suggesting the business is executing well and in line with its plan. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Following the latest results, Artemis Medicare Services' five analysts are now forecasting revenues of ₹13.6b in 2027. This would be a sizeable 22% improvement in revenue compared to the last 12 months. Per-share earnings are expected to swell 11% to ₹7.95. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹13.3b and earnings per share (EPS) of ₹8.47 in 2027. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts.
See our latest analysis for Artemis Medicare Services
The consensus price target held steady at ₹337, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Artemis Medicare Services at ₹343 per share, while the most bearish prices it at ₹325. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Artemis Medicare Services' rate of growth is expected to accelerate meaningfully, with the forecast 30% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 16% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 18% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Artemis Medicare Services is expected to grow much faster than its industry.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at ₹337, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Artemis Medicare Services analysts - going out to 2029, and you can see them free on our platform here.
You can also view our analysis of Artemis Medicare Services' balance sheet, and whether we think Artemis Medicare Services is carrying too much debt, for free on our platform here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.